Biotechnology

RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals

TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a manufacturing agreement with Cosmo Pharmaceuticals NV (SIX: COPN) ("...

2021-01-28 22:03 5222

Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK

MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021 /PRNewswire/ -- Sai Life Sciences, one ofIndia's fastest growing Contract Research, Development & Manufacturing Organizations  (C...

2021-01-28 15:30 2888

Women's reproductive healthcare in Asia gets boost with first at-home blood-testing kit for female fertility

BANGKOK, Jan. 28, 2021 /PRNewswire/ -- Health start-up Yesmom announced today its launch ofAsia's first at-home blood testing kits for female fertility, designed to help women stay on the front foot of their reproductive health from the comfort of home.

2021-01-28 10:16 1948

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemotherapy at IASLC WCLC 2020

SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEx: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that results from a cohort of Chinese patien...

2021-01-28 10:15 4427

Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease

DUBLIN, Jan. 28, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, announced today thatJapan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft...

2021-01-28 09:00 4751

Transnetyx, One Codex Build Strategic Partnership to Provide a Complete Microbiome Analysis Service for Both Mice and Humans

MEMPHIS, Tenn., Jan. 27, 2021 /PRNewswire/ -- Transnetyx, Inc. announced today its collaboration with One Codex on an end-to-end microbiome sequencing and analysis service. This offering will be driven by Transnetyx's wide-reaching global footprint in the model organism community and One Codex's ...

2021-01-28 03:29 1240

Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer

WUHAN, China and NEWARK, Del., Jan. 27, 2021 /PRNewswire/ -- Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Off...

2021-01-27 21:00 1496

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical compa...

2021-01-27 20:00 4686

Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial inChina to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001)...

2021-01-26 23:45 1279

Precision Medicine Leader Caprion-HistoGeneX Rebrands as CellCarta

MONTREAL, Jan. 26, 2021 /PRNewswire/ -- Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity.

2021-01-26 21:23 4202

Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales

INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excelle...

2021-01-26 15:00 6207

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE  (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...

2021-01-26 01:18 5828

China Biologic Announces Extraordinary General Meeting of Shareholders

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...

2021-01-25 21:44 8976

BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program

VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...

2021-01-25 21:00 3086

KPMG announces Top 50 Biotech Enterprises in the Greater Bay Area

HONG KONG, Jan. 25, 2021 /PRNewswire/ -- The third annual Guangdong-Hong Kong-Macao Greater Bay Area ("GBA") Leading Biotech 50 Awards Ceremony and Biotech Innovation and Development Summit ("the Summit") was recently held in Nansha,Guangzhou, where the list of the top 50 innovative biotech compa...

2021-01-25 16:35 2279

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-25 08:20 2717

HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC)

SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- HistoIndex 's stain-free AI digital pathology platform, incorporating Second Harmonic Generation (SHG), holds promise as a quantitative tool in the assessment of morphological and architectural changes in collagen fibers w...

2021-01-25 06:00 1829

Happiness Biotech Announces Financial Results for the Six Months Ended September 30, 2020 and Provides Guidance For the Whole Fiscal Year Ending March 31, 2021

NANPING, China, Jan. 22, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months endedSeptember 30, 2020 and provided the guida...

2021-01-22 21:00 11287

Nanoform's Clinical Study Indicates Positive Interim Results

HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received...

2021-01-22 15:43 1663

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

- ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, inEurope - Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN FLORENCE, Italy, Ja...

2021-01-22 02:25 3303
1 ... 259260261262263264265 ... 306

Week's Top Stories